Chengde Wu

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

G. Joberty, N. Zinn, M. Cheung, 2018, ACS medicinal chemistry letters.

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR.

J. Li, Shuhui Chen, Jikui Sun, 2018, ACS medicinal chemistry letters.

Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.

Yuchuan Zhu, Weifeng Mao, Shuhui Chen, 2019, ACS medicinal chemistry letters.

Discovery of 3-Quinazolin-4(3H)-on-3-yl-2,N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors.

Shuhui Chen, Tao Yu, Bei Wang, 2020, ACS medicinal chemistry letters.

Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.

R. Keenan, M. Cheung, A. Oliff, 2021, ACS medicinal chemistry letters.

Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.

Qi Li, D. Yao, Shuhui Chen, 2018, Bioorganic & Medicinal Chemistry Letters.